Oncology Peer Review On-The-Go: 1-on-1 with Dr. Xu Ji: Mental Health Among Cancer Survivors

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD

April 14th 2025

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC

Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.

Ariana Pelosci

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Administering 177Lu for mCRPC is a “team sport”, according to Steven Finkelstein, MD, DABR, FACRO.

Related Content

Elyse Swallow;Jessica Maitland;Kirthana Sarathy;Ellen Sears;Yasir Nagarwala;Janelle DePalantino;Eric Kruep;Corey Pelletier;Sebastian Kloss;Tomer Wasserman

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD

April 14th 2025

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC

Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.

Ariana Pelosci